JPRN-jRCT2080221068未知3 期
Phase III Clinical Study of YP-18 in Intra-Abdominal Infections
试验速览
- 阶段
- 3 期
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who suffer intra-abdominal infections or hepatobiliary infections clinically demonstrated by the inflammatory, abdominal or imaging findings, and who meet any of the following criteria:
- •1) Patients who are to undergo surgical procedure, percutaneous drainage of infectious lesion or gallbladder/bile duct (biliary) drainage, or underwent such treatment within 24 hours. Patients who suffer pelvic inflammatory disease or cholecystitis but whose treating physicians do not perform drainage at their discretion can be also selected as the subjects. (In the latter case, collection of aspiration samples is also required.)
- •2) Patients who suffer postoperative infections. In such cases, the gastrointestinal tract fluid or purulent discharge from the drains left during surgery should be confirmed.
- •3) Patients who are diagnosed with acute cholecystitis or acute cholangitis.
排除标准
- 未提供
研究者
相似试验
未知
3 期
Clinical phase III study of YP-18 for febrile neutropeniaJPRN-jRCT2080221686Taiho Pharmaceutical Co., Ltd.110
已完成
4 期
A Phase IV Clinical Trial of EMPYNASE P Tablets 18000 in Patients with ankle swelling after lateral ankle sprain injuries.ankle swelling after lateral ankle sprain injuries.JPRN-UMIN000009218Kaken Pharmaceutical Co., LTD200
已完成
4 期
A Phase IV Clinical Trial of EMPYNASE P Tablets 18000 in Patients with Chronic Respiratory Disease.Patients with expectoration symptom in acute exacerbation of bronchial asthma or chronic obstructive pulmonary disease.JPRN-UMIN000008534Kaken Pharmaceutical Co., LTD.240
已完成
2 期
Phase II study of intravenous and intraperitoneal paclitaxel combined with S-1 for gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000002850Department of Surgical Oncology, The University of Tokyo56
已完成
1 期
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal ImpairmentRenal ImpairmentNCT00750620Astellas Pharma Inc33